Case-Based Exchange: AV Dosing and AE Management in Patients With Untreated CLL

In the last video of this series, Mary Elizabeth DiLorenzo, MSN, RN, NP-BC, and Jamila Brutus, MSN, BSN, ANP-BC, RN, focus on adverse events (AEs) with fixed-duration acalabrutinib + venetoclax (AV). Together, they discuss best practices from their institutions for identifying and managing AEs to balance treatment efficacy with the patient’s quality of life.

In the second video of this series, Mary Elizabeth DiLorenzo, MSN, RN, NP-BC, and Jamila Brutus, MSN, BSN, ANP-BC, RN, discuss the long-term follow-up of their previously discussed patient case. Together, their perspectives show the entire clinical journey of a patient with CLL and what to consider in both the short and long term when selecting treatment.

In the first video of this series, Mary Elizabeth DiLorenzo, MSN, RN, NP-BC, and Jamila Brutus, MSN, BSN, ANP-BC, RN, introduce a complex patient case to explore best practices in utilizing and managing AEs with fixed-duration acalabrutinib + venetoclax (AV) for untreated CLL. Together, their perspectives underscore the multifaceted approach needed to select the optimal treatment option for patients with CLL.